JNJ - Johnson & Johnson
One of the world's most diversified healthcare companies, spanning prescription pharmaceuticals, medical technology, and a legacy consumer brands portfolio.
Finlify Score
57.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$265.58
-0.29%
52W Range
$173.33 - $281.07
Market Cap
$640.7B
-0.3%Compared to previous day
2026 Q1 Revenue
$24.1B
-2.0%Changes from last reporting quarter
2026 Q1 EPS
$2.14
Diluted shares
Analyst Rating
31 analysts in latest ratings feed
RSI
44.2
40-70 moderate
2Y Range Position
89%
-5.5% from high / +88.8% from low
Beta
0.21
Relative to market benchmark
MACD
-1.13
MACD line 2.19 / signal line 3.32
Fundamental Trend
Growth 33.1Financial Health
Quality 75.7Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD57.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $24.1B-2.0% | $24.6B+2.4% | $24.0B+1.1% | $23.7B+8.5% |
| Gross Profit | $16.0B-3.9% | $16.6B-0.6% | $16.7B+3.6% | $16.1B+10.9% |
| Operating Income | - | - | - | - |
| Net Income | $5.2B+2.3% | $5.1B-0.7% | $5.2B-7.0% | $5.5B-49.7% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
Finlify's signal for JNJ is a HOLD, with a Finlify Score of 59.5 out of 100, suggesting a balanced outlook based on its underlying component scores.
Technical
The asset exhibits moderate Relative Strength at 59.1/100, while Accumulation / Volume appears strong at 82.8/100. Its RSI(14) of 51.7 suggests it is neither significantly overbought nor oversold, and the 60-day return of 14.1% indicates recent positive momentum, despite being -4.3% from its 52-week high.
Fundamentals
The Fundamental Trend score of 33.1/100 appears relatively low, potentially indicating some headwinds, though Financial Quality remains robust at 75.7/100. JNJ's valuation metrics, such as a P/E of 23.2x and P/B of 6.1x, may suggest a premium, while its low Beta of 0.2 indicates lower volatility and a stable dividend yield of 2.10%.
Macro Context
In a macro environment with CPI YoY at 3.7% and Core CPI at 2.8%, JNJ's defensive nature and dividend yield of 2.10% may offer some stability. The positive yield spread of 0.5% (10Y-2Y) and 4.2% unemployment rate could suggest a moderately stable economic backdrop, which might still favor established, less cyclical companies.
Key Risks
- The relatively low Fundamental Trend score of 33.1/100 may suggest underlying business challenges or decelerating growth prospects.
- Valuation metrics such as a P/E of 23.2x and P/B of 6.1x could indicate the asset is trading at a premium compared to historical averages or peers.
- Despite recent positive 60-day returns, the asset's current price is still 4.3% below its 52-week high, which might suggest some resistance or a recent pullback from peak levels.